VANCOUVER, British Columbia, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that it has entered a memorandum of understanding (“MOU”) with AlcoPro Inc. (“AlcoPro”) of Knoxville, TN, to begin collaborating on marketing efforts for the Cannabix Marijuana Breathalyzer (“CMB”) technology in the United States. In the short-term, AlcoPro will include the CMB hardware in its upcoming 2025 product catalogue, mailed to over 70,000 businesses in U.S. and globally. AlcoPro is a well-established distributor and leading supplier of drug and alcohol testing instruments, kits, and supplies for professional use, since 1982.
The objective of the MOU is to establish preliminary marketing exposure of the CMB to AlcoPro customers, gauge interest and work towards a future distribution agreement. Cannabix recently upgraded its Breath Collection Unit (“BCU”) – a critical hardware tool used for portable collection of delta-9 THC in breath (image below). Cannabix is quickly advancing its marijuana breathalyzer technology, with key validation work well underway in the United States.
Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology
Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology.
Rav Mlait, CEO of Cannabix stated, “We are very pleased to be building a relationship with AlcoPro to begin preliminary marketing of our technology. The Company continues to advance its marijuana breathalyzer technology with key scientific validations and testing which are well underway.”
Brian Terry, Director of Business Development of AlcoPro stated, “We are thrilled to establish a relationship with Cannabix Technologies, broadening our focus from providing physical testing tools to embracing innovative technologies that address the growing need for accurate and reliable THC detection. As workplace safety challenges evolve, it’s critical to stay at the forefront of solutions that proactively mitigate risks and ensure a safer environment for employees.”
About AlcoPro, Inc.
Since 1982, AlcoPro has been a trusted leader in drug and alcohol testing solutions for employers, healthcare professionals, law enforcement, and substance abuse specialists. Known for reliable instruments like market-leading breathalyzers, AlcoPro also offers innovative online training with interactive tools to enhance knowledge retention. With a comprehensive product catalog, easy online ordering, and expert support, AlcoPro makes workplace testing simple, accurate, and professional. Learn more at www.AlcoPro.com.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the primary psychoactive ingredient in cannabis. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of its Breath Logix Series of breath alcohol detection devices for employers and a range of other settings.
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: the achievement of any or all of the goals and aims of an “MOU” or partnerships as described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with existing and new partners; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that partners may not complete all or any of the milestones as contemplated strategic partnership agreements; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
